Therapeutic trials in neuromuscular diseases
โ Scribed by Walter G. Bradley
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 76 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0148-639X
No coin nor oath required. For personal study only.
โฆ Synopsis
T h e treatment of a disease may spring from an understanding of the underlying etiology of that disease, or it may arise less directly. For instance, the use of L-dopa in the treatment of Parkinson's disease arose from the finding of deficient dopamine levels in the brains o f Parkinsonian patients. On the other hand, the recognition of the existence of vitamin B-12 and its use in preventing the anemia and complications of Pernicious Anemia arose from the demonstration that liver contained an agent capable of increasing hemopoiesis in such paticnts. Therapeutic trials may therefore play an important part both in dewloping an cffective treatment, and in increasing the understanding of the underlying ctiology o f the disease.
๐ SIMILAR VOLUMES
Dr. Hamburger was asked whether he would recommend the use of cytoxin or lymphacytapheresis first in the treatment of rheumatoid arthritis. He stated that he would recommend lymphacytapheresis first, especially in relatively young patients because of the multiple side effects and the risk of long-te
This review summarizes the current status of intravenous immunoglobulin (IVIg) in the treatment of autoimmune neuromuscular disorders and the possible mechanisms of action of the drug based on work in vivo, in vitro, and in animal models. Supply of idiotypic antibodies, suppression of antibody produ
The association of malignant hyperthermia (MH) with neuromuscular disorders has been recognized since 1970. These disorders include central core disease, Duchenne muscular dystrophy, myotonia congenita, myotonic dystrophy, nonspecific myopathies, and King-Denborough syndrome. In order to assess the